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Abstract 
This study investigated the effects of leucine or leucine + glutamine supplementation on 
recovery from eccentric exercise. In a double-blind independent groups design, 23 men were 
randomly assigned to a leucine (0.087 g/kg; n = 8), leucine + glutamine (0.087 g/kg + glutamine 
0.3 g/kg; n = 8) or placebo (0.3 g/kg maltodextrin; n = 7) group. Participants performed 5 sets 
of drop jumps, with each set comprising 20 repetitions. Isometric knee-extensor strength, 
counter-movement jump (CMJ) height, delayed onset muscle soreness (DOMS) and creatine 
kinase (CK) were measured at baseline, 1 h, 24 h, 48 h and 72 h post-exercise. There was a 
time × group interaction for isometric strength, CMJ and CK (P < 0.05), with differences 
between the leucine + glutamine and placebo group at 48 h and 72 h for strength (P = 0.013; d 
= 1.43 and P < 0.001; d = 2.06), CMJ (P = 0.008; d = 0.87 and P = 0.019; d = 1.17) and CK at 
24 h (P = 0.012; d = 0.54) and 48 h (P = 0.010; d = 1.37). The leucine group produced higher 
strength at 72 h compared to placebo (P = 0.007; d = 1.65) and lower CK at 24 h (P = 0.039; d 
= 0.63) and 48 h (P = 0.022; d = 1.03). Oral leucine or leucine + glutamine increased the rate 
of recovery compared to placebo after eccentric exercise. These findings highlight potential 
benefits of co-ingesting these amino acids to ameliorate recovery.  
 
Key words: Amino Acids, muscle damage, recovery, supplementation, exercise. 
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Introduction  
Specific forms of exercise require eccentric muscle loading patterns, such as plyometric 
training (Twist et al., 2008), which increase the amount of mechanical stress on the muscle. 
During eccentrically-biased exercise, the external forces applied to muscle groups overcome 
their internal resistance, resulting in the muscle lengthening under tension (Howatson and van 
Someron 2008). During eccentric contractions, lower muscle activation and preferential 
recruitment of fast-twitch fibres leads to greater tension per muscle fibre and a bias toward type 
II muscle fibre damage (Shepstone et al., 2005). Loading the lengthening muscle under-tension 
causes greater myofibrillar damage and so-called sarcomere popping, indicating mechanical 
damage to the cellular structures (Leiber and Friden, 1999). As a result, exercise–induced 
muscle damage (EIMD) is typically observed after resistance exercise but is exacerbated when 
eccentric exercise is performed, relative to concentric exercise at the same intensity (Proske 
and Morgan, 2001). This can be intended by the athlete to promote muscle growth by inducing 
greater mechanical tension, thus disturbing the integrity of skeletal muscle and promoting 
microdamage in muscle fibres (Schoenfeld, 2010; 2012).  
 
In the days (24-72 h) following eccentrically-biased exercise, EIMD is manifested by a 
transient decrease in force production, delayed-onset muscle soreness (DOMS) and leakage of 
intramuscular proteins into the circulation (i.e. creatine kinase; CK) (Sorichter et al., 1999). 
The derangement of intracellular Ca2+ homeostasis, caused by the insult of heavy resistance 
exercise, initiates a cascade of intra-cellular events that lead to the activation of proteolytic and 
lipolytic pathways, thus damaging cellular structures (Gissel and Clausen 2001). These 
processes give rise to a secondary inflammatory phase, whereby protein uptake is increased for 
use as an energy substrate or to mediate cell signalling pathways that are necessary for muscle 
and connective tissue remodelling (Nicastro et al., 2012).  
 
Given the demands of frequent resistance training, full and rapid recovery between bouts of 
exercise is desirable. Therefore, interventions that help to attenuate the effects of muscle 
damage are beneficial to the athlete by reducing the decline in physical function and permitting 
greater engagement with training in the days following exercise (Cheung et al., 2003; Proske 
and Morgan, 2001; Howatson and van Someren, 2008). One type of branched-chain amino acid 
(BCAA), namely leucine, can be prophylactically ingested to attenuate symptoms of muscle 
damage (da Luz et al., 2011). Supplementation of leucine has been suggested to suppress 
muscle proteolysis (Zanchi et al., 2008) and reduce protein oxidation (Shimomura et al., 2009) 
after muscle-damaging exercise, thus helping to balance protein turnover in the cell, as well as 
maintaining the integrity of the muscle cell membrane. Indeed, muscle protein synthesis is 
directed toward the repair or remodelling of structural and contractile proteins in the days after 
muscle-damaging exercise (McGlory et al., 2017). This is relevant because skeletal muscle 
proteins, such as CK, lactate dehydrogenase (LDH) or myoglobin (Mb), are known to exit the 
cell and indirectly infer cellular damage, acting as surrogate markers of muscle damage. For 
example, Kirby et al. (2012) reported reductions in serum Mb and CK concentration 24 h 
following eccentrically-biased exercise after subjects were supplemented with 250 mg/kg body 
mass of leucine 30 min before, during and immediately post-exercise and the morning of each 
recovery day.  
 
Whist leucine is an effective recovery supplement when co-ingested with other BCAAs 
(Howatson et al., 2012; Waldron et al., 2017), it is possible that leucine is more effective for 
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cellular recovery when it is not mixed with BCAA solutions. This may be due to the reported 
competition between leucine, isoleucine and valine for cellular transport (Cynober, 2002). 
Indeed, the combination of leucine with other amino acids (AA), such as glutamine, has greater 
theoretical support. This relates to the putative roles of leucine during the acute inflammatory 
phase of muscle damage (see Rowlands et al., 2016), which relies upon the known 
transamination of leucine into glutamate. This process effectively contributes to the glutamate-
glutamine pool (Golden et al. 1982), which is a substrate for inflammatory cells (Gleeson, 
2008). Indeed, given the numerous cellular interactions between glutamine and leucine 
(Nicastro et al., 2012), it is possible that optimal combinations of leucine and glutamine would 
ameliorate recovery through anti-inflammatory processes. Glutamine, ingested alone, has also 
been shown to reduce strength losses following eccentric exercise (Street et al., 2011). 
However, there is no study examining the effects of leucine, in combination with other anti-
inflammatory amino acids, on the recovery from muscle damaging exercise. 
 
Therefore, the aim of this study was to investigate the effects of acute body-mass dependent 
leucine or leucine + glutamine supplementation on recovery from eccentrically-biased exercise 
among recreational athletes. It was hypothesized that the leucine or leucine + glutamine 
supplementation would attenuate symptoms of muscle damage compared to the placebo group, 
but that the co-ingestion group would have the largest effects on recovery.  
Methods 
Participants 
Twenty three males (mean ± SD age 21 ± 1 years, stature 180.2 ± 6.1 cm, body mass 86.5 ± 
7.9 kg) consented to take part in this study. A total sample of 18 was required, based on an 
effect size of 0.5 and statistical power of 0.95. Informed consent was obtained from all 
individual participants included in the study. All participants were recreationally resistance-
trained athletes, with a minimum of one year training history. To be included in this study, the 
participants had to be injury-free and train on a weekly basis using a mixture of resistance 
exercises. Participants were initially screened for any recent injuries or movement 
compensations that may cause pain or discomfort when performing the movements to be 
included in the study (i.e. drop-jumps). Ethical approval was granted for this study by the 
Institutional ethics committee. All procedures were performed in accordance with the ethical 
standards of the institutional research committee and with the 1964 Helsinki declaration and 
its later amendments or comparable ethical standards. 
 
Design 
Two weeks prior to testing, participants were told to cease any use of nutritional supplements, 
additional to their normal diet, such as protein supplements, creatine and AA. The participants 
were advised to avoid any drugs with anti-inflammatory properties and not to use compression 
garments or seek therapeutic intervention, such as hydrotherapy treatments or forms of 
massage. Participants were also provided with daily diet suggestions to follow from 48 h before 
the study until their final testing day. This comprised a macronutrient composition of 50% 
carbohydrate, 15% protein (of similar amino acid content) and 35% fat. The participants visited 
the laboratory at the same time of day on five separate days, approximately 2 h after eating 
breakfast. During visit 1, the participants were familiarized with the testing procedures and 
were weighed for subsequent calculation of the leucine supplement. The participants were also 
familiarised with the muscle soreness scale and muscle function test, as well as the specific 
instructions for how to perform a drop jump, including intensity and technique, as this would 
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be the mode of muscle-damage during the study. Familiarization was deemed to be sufficient 
after one visit as the participants were consistent in their performance on all tests and indicated 
that they were comfortable in performing them.  
 
After visit 1, the participants were assigned to one of the three conditions by an independent 
laboratory technician (leucine, leucine + glutamine or placebo) in a double-blind, independent 
groups design. The participants were matched on their counter-movement jump height to 
ensure a baseline similarity in a functional measure of physical fitness, which was determined 
at familiarisation. The randomisation was carried out by assigning each participant a number 
and using publicly available software to allocate their group (http://www.randomization.com/). 
  
Visit 2 was carried out 72 hours after visit 1, with no other exercise performed in between. At 
visit 2, the participants had capillary blood samples drawn from the finger for the measurement 
of baseline CK and then performed a battery of baseline tests in the following order: perceived 
soreness, lower-limb isometric strength and countermovement jumping. After the baseline 
testing, participants were given the supplement and 30 min later they were supervised through 
the muscle-damage protocol. Following this, a second supplement was ingested and 30 min 
later the battery of tests were repeated. Visits 3, 4 and 5, took place at 24 h, 48 h and 72 h, 
respectively, after the initial muscle damage protocol. At each of these visits the same battery 
of tests was performed before and after the muscle damage protocol. At visits 3 and 4, 
supplements were provided 30 mins before and 30 min after the muscle damage protocol. At 
visit 5, a morning supplement was provided, as well as the final supplement, 30 min prior to 
the muscle damage protocol.  
 
Procedure 
Knee-extensor isometric strength  
To test the maximal isometric strength of the knee-extensor muscles, each participant sat on a 
custom made, adaptable strength chair, with their back and knees fully supported. Their knee 
was firmly fixed at 100˚ and their hips at 110˚, which was verified using a goniometer. Their 
right leg was firmly strapped to the chair across the mid-thigh, whilst their ankle (immediately 
above malleoli) was fixed to a strain gauge (Interface SSM-AJ-500 Force Transducer; 
Interface, Scottsdale, AZ; 0.05% maximum error), sampling at 1000 Hz. The strain gauge 
recorded force as alteration in voltage. Calibration of the strain gauge with a known mass 
demonstrated the relationship between voltage and Newtons as linear, allowing determination 
of a regression formula to convert voltage to Newtons. A second calibration was performed 
with the same weights at the completion of testing, producing an ICC of 0.99. The strain gauge 
was attached to the participant using a high tension belt. The chair set-up was replicated for 
each participant in subsequent trials. The participants’ upper-body was also tightly fitted to the 
chair with two stabilisation straps across each shoulder, which they were instructed to grip with 
their hands throughout the testing. A command of ‘3-2-1-GO’ was given, after which the 
participants performed a maximal isometric knee extension for 5 s. Non-specific verbal 
encouragement was provided to the participants for motivation. Participants performed three 
maximal tests, separated by 2 min. A maximal voluntary contraction was determined as the 
highest of three values and recorded for analysis. If the peak force (N) produced by participants 
systematically increased across the three tests, a fourth test was conducted. The reliability of 
this procedure was 2% (coefficient of variation; CV). 
5 
 
Counter-movement jumping (CMJ) 
Participants performed a CMJ on a jump mat (Probiotics Inc, Huntsville, AL, USA) by standing 
with their feet at shoulder width, hands on hips and descending to ~90˚ before propelling 
themselves vertically to the highest possible height, keeping their legs fully extended. 
Standardised non-specific motivation and cues were provided to facilitate performance. The 
participants performed three jumps, separated by 2 min and the highest jump height (cm) was 
recorded. If the values systematically increased across the three tests, a fourth test was 
conducted. The test re-test reliability of this procedure was 1.2% (CV).  
 
Blood sampling and analysis 
The index fingertip of the subject was cleaned using a sterile alcohol swab and allowed to dry. 
Capillary blood was drawn from the finger and a sample of whole blood (30 μL) was collected 
into a heparinised capillary tube. The whole blood was centrifuged at 3000 rpm (4 °C) for 5 
min, and the resultant plasma was removed and stored at -80°C until subsequent analysis. 
Plasma CK was measured using a chemistry analyser (Rx Monza, Randox Laboratories Ltd., 
Crumlin, Antrim, UK). The intra-sample CV of the analyser is < 4% CV at high and low 
concentrations and the expected baseline sample range is 37-2755 IU/L for CK, according to 
manufacturer’s guidelines. To eliminate inter-assay variance, all samples were analysed in the 
same assay run. 
 
Perceived soreness 
The participants were asked to rate their perceived muscle soreness in the lower-limbs from 0-
10 on a 200 mm Visual Analogue Scale (VAS). The numbers were concealed from the 
participant on the reverse of the scale, whilst the verbal anchors of no muscle soreness (0 on 
reverse), soreness upon movement (5 on reverse) and too sore to move (10 on reverse) were 
observed from the front of the scale. To do this, the participants performed a 5 s isometric 
squat, with their ankles, knees and hips at 90˚ and, after 5 s, moved a sliding scale to the number 
which they perceived to correspond to their level of soreness (Howatson et al., 2012).  
 
Supplementation 
All supplements were sourced from the same company (Myprotein, Cheshire, UK). Each 
participant was supplemented with one of three supplements: a placebo, a leucine beverage or 
a leucine + glutamine beverage, all of which contained 0.3 g/kg body mass of maltodextrin 
dissolved into 300 ml of water. This ensured that the drinks were indistinguishable in taste. 
The leucine drink was provided at a high dose of 0.087 g/kg (87 mg/kg) body mass (Børsheim 
et al., 2002). This dosage of AA has been shown to promote recovery from resistance exercise 
(Børsheim et al., 2002) and is between the dosages provided in previous studies, which range 
between 22.5 mg/kg and 250 mg/kg of body mass (Stock et al., 2010; Kirby et al., 2012). The 
highest doses were not chosen so that the leucine + glutamine group could comfortably co-
ingest with an additional 0.3 g/kg body mass of glutamine (Street et al., 2011) and without 
noticing the taste or difference in the drinks consistency. Drinks were consumed 30 min before 
and after the muscle damage protocol (Jackman et al., 2010). Over the following 72 h, the 
supplements were provided 30 min before and after re-testing. On the final day, the supplement 
was taken with breakfast and 30 min before testing to provide two doses. The supplements 
were prepared by an independent laboratory technician. 
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Muscle-damage protocol 
A standardised warm-up was performed on the day, comprising walking, jogging and dynamic 
stretching. The participants then performed 5 sets of drop jumps from a 60 cm box, with each 
set comprising 20 repetitions (100 repetitions total) (Howatson et al., 2012). Participants were 
provided with 10 s between each jump, with 2 min rest between sets. All of the participants 
were able to complete the protocol.  
 
Statistical analyses 
After checks for sphericity, a two-way within and between analysis of variance was performed 
to evaluate the main effects of time (baseline, immediately post, 24 h, 48 h and 72 h post-
exercise) and group (placebo, leucine and leucine + glutamine) and their interactions on the 
dependent variables. If tests of Sphericity were violated, the Greenhouse-Giesser correction 
was used. In the event a statistical difference was identified, a post-hoc Bonferroni test was 
used to identify differences. The dependent variables were isometric strength, CK 
concentration, delayed onset muscle soreness and countermovement jump height (each 
expressed relative to baseline; %). Effect sizes (Cohen’s d) were also performed on pairwise 
comparisons and defined as; trivial = 0.2; small = 0.21–0.6; moderate = 0.61–1.2; large = 1.21–
1.99; very large > 2.0 (Batterham and Hopkins, 2006). An alpha level of P  0.05 was set for 
all analyses. Statistical analysis was conducted through IBM SPSS (Software V22.0, IBM, 
New York, USA). 
 
Results 
All absolute changes (unit-specific) are presented in Table 1. All relative changes (% baseline) 
are presented in Figures 1-4. 
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Table 1  
         Baseline Post-exercise 24 h    48 h 72 h 
Isometric strength (N) Leucine + Glutamine 743.0 ± 147.7 699.0 ± 150.8 681.8 ± 150.2 656.9 ± 146.6 760.3 ± 140.2 
 Placebo 635.4 ± 95.8 597.0 ± 99.2 567.7 ± 102 539.6 ± 102.9 614.2 ± 92.6 
 Leucine 672.4 ± 94.7 634.0 ± 85.5 605.3 ± 89.2 572.1 ± 83.9 675.1 ± 92.6 
                 
CMJ (cm) Leucine + Glutamine 32.7 ± 5.1 32.7 ± 6.2 30.9 ± 5.1 32.5 ± 5.9 34.1 ± 5.9 
 Placebo 30.1 ± 2.1 28.2 ± 2.1 27.5 ± 2.6 27.2 ± 2.7 28.6 ± 2.8 
 Leucine 33.9 ± 5.3 33.0 ± 4.9 31.9 ± 4.1 32.1 ± 3.8 33.6 ± 4.7 
                 
DOMS (0-10) Leucine + Glutamine 1.5 ± 0.5 5.3 ± 0.5 5.4 ± 0.7 4.6 ± 0.9 2.1 ± 0.6 
 Placebo 1.4 ± 0.5 5.4 ± 0.5 6.1 ± 0.4 6.0 ± 0.4 4.0 ± 0.0 
 Leucine 1.5 ± 0.5 5.4 ± 0.5 5.5 ± 0.8 5.1 ± 0.4 2.4 ± 0.5 
                 
CK (IU/L) Leucine + Glutamine 131.8 ± 54.0 298.4 ± 121.2 607.5 ± 345.2 229.6 ± 107.0 192.0 ± 100.2 
 Placebo 94.1 ± 35.6 217.7 ± 73.5 431.1 ± 128.0 245.1 ± 116.0 189.0 ± 100.8 
  Leucine 98.7 ± 26.2 230.4 ± 67.9 412.3 ± 117.2 191.6 ± 80.1 192.1 ± 108.7 
Absolute values of isometric strength (N), countermovement jump (CMJ) height (cm), delayed onset muscle soreness (DOMS; 0-10) and creatine 
kinase (CK) concentration (UI/L) at baseline, post-exercise, 24 h, 48 h and 72 h after exercise among recreationally trained participants (n = 23). 
Statistical interpretations are included on relative data in Figures 1-4.  
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Changes in isometric force (% baseline) are presented in Figure 1 (mean ± SD). There were 
main effects of time for isometric strength (F (4,80) = 135.3; P < 0.001), with post-hoc tests 
demonstrating differences between baseline and all subsequent time points (P < 0.001) apart 
from 72 h, where strength returned to baseline (P = 1.000). There was a time × group 
interaction (F (8,80) = 2.161; P = 0.039), with post-hoc tests identifying differences between the 
leucine + glutamine and the placebo group at 24 h (91.4 ± 3.4 % vs. 87.5 ± 3.2 %; P = 0.045; 
d = 1.09), at 48 h (88.1 ± 3.2 % vs. 82.6 ± 2.9 %; P = 0.013; d = 1.43) and at 72 h (102.7 ± 3.0 
% vs. 96.2 ± 3.8 %; P < 0.001; d = 2.06). The leucine group also demonstrated higher strength 
at 72 h compared to the placebo group (100.4 ± 1.2 % vs. 96.2 ± 3.8 %; P = 0.007; d = 1.65). 
 
Figure 1. Isometric knee extensor force (% baseline) at baseline, immediately post-exercise 
and 24 h, 48 h and 72 h post-exercise in placebo (n = 7), leucine (n = 8) and leucine + glutamine 
(n = 8) groups. Note: Leu = leucine; Glu = glutamine and * = sig. different between Leu+Glu 
and placebo; † = sig. different between leucine and placebo. SD bars removed for clarity. 
 
Changes in CMJ height (% baseline) are presented in Figure 2. There were main effects of time 
for CMJ height (F (4,80) = 9.538; P < 0.001), with post-hoc tests demonstrating differences 
between baseline and all subsequent time points (P < 0.001), apart from 72 h, where CMJ 
height returned to baseline (P = 1.000). There was a time × group interaction (F (8,80) = 2.734; 
P = 0.05), with post-hoc tests identifying differences between the leucine + glutamine and the 
placebo group post-exercise (99.6 ± 5.6 % vs. 93.6 ± 2.3 %; P = 0.007; d = 1.47), at 48 h (99.5 
± 7.6 % vs. 90.3 ± 5.1 %; P = 0.008; d = 0.87) and at 72 h (104.6 ± 11.0 % vs. 94.7 ± 6.2 %; P 
= 0.019; d = 1.17). There were no pairwise differences (P > 0.05) between the leucine and 
placebo group for CMJ height.   
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Figure 2. Countermovement jump height (CMJ % baseline) at baseline, immediately post-
exercise and 24 h, 48 h and 72 h post-exercise in placebo (n = 7), leucine (n = 8) and leucine + 
glutamine (n = 8) groups. Note: * = sig. different between Leu+Glu and placebo. SD bars 
removed for clarity.     
 
Changes in DOMS (% baseline) are presented in Figure 3. There were main effects of time for 
DOMS (F (4,80) = 84.114; P < 0.001), with post-hoc tests demonstrating differences between 
baseline and all subsequent time points, including 72 h (P < 0.001). There was no time × group 
interaction (F (8,80) = 1.473; P = 0.181) but effect size estimates demonstrated large differences 
between the leucine + glutamine and placebo groups (d = 1.31 and d = 1.40) and leucine and 
placebo groups (d = 1.21 and d = 1.38) at 24 h and 48 h, respectively.    
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Figure 3. Delayed onset muscle soreness (DOMS % baseline) at baseline, immediately post-
exercise and 24 h, 48 h and 72 h post-exercise in placebo (n = 7), leucine (n = 8) and leucine + 
glutamine (n = 8) groups. SD bars removed for clarity. 
 
Changes in CK (% baseline) are presented in Figure 4. There were main effects of time for CK 
(F (4,80) = 4.616; P = 0.009), with post-hoc tests demonstrating differences between baseline 
and 24 h (P < 0.001). There were interactions between group and time (F (4,80) = 2.319; P = 
0.046), with post-hoc tests revealing differences between the leucine + glutamine and the 
placebo group at 24 h (437.6 ± 86.4 % vs. 501.6 ± 161.8 %; P = 0.012; d = 0.54) and 48 h 
(171.2 ± 31.7 % vs. 281.3 ± 122.0 %; P = 0.010; d = 1.37), as well as the leucine and placebo 
group at 24 h (426.8 ± 89.6 % vs. 501.6 ± 161.8 %; P = 0.039; d = 0.63) and 48 h (193.5 ± 54.4 
% vs. 281.3 ± 122.0 %; P = 0.022; d = 1.03). 
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Figure 4. Creatine kinase concentration (CK % baseline) at baseline, immediately post-
exercise and 24 h, 48 h and 72 h post-exercise in placebo (n = 7), leucine (n = 8) and leucine + 
glutamine (n = 8) groups. * = sig. different between Leu+Glu and placebo; † = sig. different 
between leucine and placebo. SD bars removed for clarity. 
 
Discussion 
All of the participants exhibited signs of muscle damage in this study and, in support of our 
hypothesis, co-ingestion of leucine and glutamine improved the rate of recovery after 
eccentrically-biased exercise more than placebo and leucine alone. The effects of co-ingested 
leucine and glutamine were such that all of the functional variables (i.e. isometric strength, 
CMJ) returned to baseline at the greatest rate. The leucine group also recovered faster than the 
placebo group but not by the same magnitude as the co-ingestion group. This was particularly 
notable for measures of isometric strength and CMJ, which are established measures of the 
time-course and magnitude of recovery after muscle damaging exercise (Byrne et al., 2004). 
The differences between groups were predominantly noted at the 24-48 h period, with the 
leucine + glutamine group demonstrating ‘moderate-large’ improvements in strength, CMJ, 
DOMS and CK compared to placebo (Figures 1-4). These findings demonstrate a faster return 
to baseline values and indicate that the combination of a well-known proteinogenic amino acid 
(leucine), with an anti-inflammatory amino acid (glutamine), confers the greatest effects on 
recovery. 
 
Acute supplementation of isolated leucine at doses of 22.5 mg/kg (Stock et al., 2010) and 250 
mg/kg of body mass (Kirby et al., 2012) has been shown to ameliorate recovery from muscle 
damaging exercise. For example, Kirby et al. (2012) reported an improvement in recovery of 
isometric strength (~ 5 %) after muscle damage, using a short-term (beginning 30 min prior to 
exercise) leucine supplementation regime, similar in timing to the current study. In 
combination with other BCAAs, leucine has been repeatedly shown to increase the rate of 
recovery from muscle damaging exercise (Howatson et al., 2012; Jackman et al., 2010; 
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Matsumoto et al., 2009; Waldron et al., 2017). While some have reported no change in muscle 
damage markers following BCAA supplementation (Kephart et al., 2016; Ra et al., 2013), this 
could be related to the relatively small doses (~ 3-5 g) provided compared to other studies (15-
20 g; Waldron et al., 2017; Howatson et al., 2012). Whilst there are putative roles for all 
BCAAs in muscle protein synthesis (Blomstrand et al., 2006), leucine is known to confer the 
most potent anabolic signalling effects, whereas isoleucine and valine have negligible 
contributions (Atherton et al., 2010). This is most likely worsened by the reported competition 
between leucine, isoleucine and valine for cellular transport, following co-ingestion (Cynober, 
2002). Leucine is also known to inhibit muscle proteolysis, thus maintaining muscle protein 
balance (Baptista et al., 2010). Since both of the current supplements improved the recovery 
from eccentric exercise and each contained leucine, the role of leucine in reducing symptoms 
of muscle damage are apparent and support that of other studies (Kirby et al., 2012; Stock et 
al., 2010). Furthermore, the magnitude of change in isometric force production was similar, or 
greater, than previously reported with BCAA supplementation (Howatson et al., 2012; 
Waldron et al., 2017), providing further indirect support for the ergogenic effects of isolated 
leucine, relative to co-ingestion.   
 
Glutamine can be classified as an anabolic and immunostimulatory AA, owing to its 
participation in myogenic signalling pathways and role as a substrate for leukocytes, 
respectively (Gleeson, 2008). Oral glutamine supplementation (0.3g/kg body mass) reduces 
strength loss following an acute bout of eccentrically-biased exercise (Legault et al., 2014; 
Street et al., 2011), which was attributed to both its anti-inflammatory role and involvement 
with protein synthesis pathways. Indeed, both glutamine and leucine possess anti-inflammatory 
properties. For example, Cruzat et al. (2010) supplemented rats with 1.5 g/kg of glutamine for 
3 weeks, reporting lower post-exercise concentrations of pro-inflammatory cytokines. 
Administration of leucine-rich AA has also been shown to reduce the appearance of 
inflammatory cytokines, whilst increasing muscle protein synthesis after both eccentric 
exercise in rodents (Kato et al., 2016) and endurance exercise in athletes (Rowlands et al., 
2016). Rowlands et al. (2016) provided 15 g of leucine to athletes as part of a balanced 
macronutrient recovery meal. The authors demonstrated decreased leukocyte migration and 
connective tissue development, indicating the acute anti-inflammatory and proteinogenic 
properties of leucine rich supplementation. These processes provide a logical explanation for 
the descriptive reductions in DOMS herein (ES = large), as muscle soreness is partly related 
to local inflammation, whereby local swelling acts to sensitise nociceptors located in the 
muscle (Proske and Morgan, 2000). Therefore, whilst inflammation is a necessary part of the 
recovery process that follows acute mechanical damage of the myofibres (Howatson and van 
Someren, 2008), its reduction could reduce the perceived limb soreness of athletes and 
accelerate their recovery from eccentric exercise.   
 
Given that the co-ingestion of glutamine and leucine provided the greatest effect on recovery 
in this study, it is necessary to provide some speculation on their potential interaction in vivo. 
Leucine is an essential nitrogen donor in the synthesis of glutamine. Once inside the cell, 
leucine reversibly transaminates to glutamate, particularly during short periods of high-
intensity exercise (Henriksen, 1991), thus contributing to the glutamate-glutamine pool (Aoki 
et al., 1981; Golden et al 1981). The influx of leucine into the cell is also dependent on the 
efflux of glutamine, owing to the integrated transport systems of these AA (Nicastro et al., 
2012). Indeed, under certain physiological conditions, it has been shown that glutamine 
transport into the cell, via its transporter SLC1A5, is rapidly used to facilitate the influx of 
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extracellular leucine via an efflux of glutamine through a bidirectional SLC7A5/SLC3A2 
transporter, which can subsequently activate the mammalian target of rapamycin complex 
(mTOR) complex (Nicklin et al., 2009). Therefore, it is likely that the exogenous supply of 
glutamine, administered herein, might have provided a greater stimulus for leucine uptake into 
the cell, as it is known that oral supplementation of glutamine or leucine increases plasma 
concentrations (Churchward-Venne et al., 2014; Rowlands et al., 2016) and transport of leucine 
into the cell in the post-absorptive state. The transport of leucine into the muscle cell is 
necessary prior to its participation in protein synthesis or before contributing to the intracellular 
glutamine content. Therefore, co-ingesting leucine and glutamine could i) facilitate transport 
of leucine into the cell and ii) contribute to the glutamine-glutamate pool, thereby iii) sparing 
free leucine and increasing its availability.  
 
The current study is limited by the number of experimental groups that were included. It is 
possible that the effects we have observed are related to the higher energy or amino acid content 
of the leucine + glutamine group, rather than the specific combination of amino acids. 
Similarly, the placebo group did not ingest any additional amino acids outside of their normal 
diet. We opted to investigate a fixed dose of leucine, rather than an isocaloric dose, to establish 
whether the effects of the isolated leucine dose could be enhanced. This dose provided an 
average ~ 15/day of leucine in the current participants, which was deemed to be suitable, given 
that 5 g of leucine has been considered as ‘high’ and sufficient to increase muscle protein 
synthesis above higher doses of whey protein supplements (Churchward-Venne et al., 2014). 
Nevertheless, our results show that recovery from eccentric exercise, facilitated by acute doses 
of leucine, can be improved by adding glutamine or additional AA to the ingested supplement. 
Future research should consider adding additional energy- or AA-matched groups to the current 
research design to establish this.     
 
Conclusion 
Acute oral supplementation of leucine (0.087 g/kg) or leucine + glutamine (0.087 g/kg + 0.3 
g/kg) increased the rate of recovery in isometric strength, CMJ height, DOMS and CK 
compared to placebo after eccentrically-biased exercise. Based on a 100 kg athlete 
supplementing twice daily, 17.4 g of leucine, plus 30 g of glutamine would be necessary to 
accelerate recovery. However, further studies are required to understand whether the provision 
of an iso-caloric or iso-amino acid supplement would achieve the same effect.  
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